Humana (NYSE:HUM) Rating Lowered to Equal Weight at Stephens

Humana (NYSE:HUM) was downgraded by investment analysts at Stephens from an “overweight” rating to an “equal weight” rating in a note issued to investors on Wednesday, MarketBeat Ratings reports. They currently have a $250.00 price objective on the insurance provider’s stock, down from their prior price objective of $400.00. Stephens’ price objective suggests a potential upside of 3.43% from the stock’s current price.

Several other analysts have also recently weighed in on HUM. Truist Financial boosted their price objective on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, July 15th. Royal Bank of Canada increased their price objective on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, September 5th. Piper Sandler started coverage on shares of Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Finally, Oppenheimer raised their price target on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $360.86.

Humana Price Performance

HUM opened at $241.72 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The stock has a market capitalization of $29.13 billion, a P/E ratio of 15.05, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50. The company’s 50 day simple moving average is $340.75 and its 200-day simple moving average is $342.90. Humana has a one year low of $213.31 and a one year high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $8.94 EPS. Sell-side analysts anticipate that Humana will post 16.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humana

Several institutional investors have recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. raised its holdings in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Hantz Financial Services Inc. acquired a new stake in Humana in the 2nd quarter valued at $35,000. Family Firm Inc. bought a new stake in Humana during the 2nd quarter worth about $37,000. Hollencrest Capital Management bought a new stake in Humana during the 2nd quarter worth about $40,000. Finally, Riverview Trust Co acquired a new position in shares of Humana during the 2nd quarter worth about $44,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.